A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

NCT05133349 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Advanced or Metastatic Paraganglioma/ Pheochromocytoma

Interventions

DRUG: Anlotinib

Sponsor

Nanjing First Hospital, Nanjing Medical University